EFFECTS OF PEMBROLIZUMAB ON THE TUMOR MICROENVIRONMENT (TME) AFTER ONE PRESURGERY TREATMENT CYCLE IN PATIENTS WITH TRIPLE-NEGATIVE BREAST CANCER (TNBC): PHASE 1B KEYNOTE-173 STUDY

被引：2
|
作者：
Schmid, Peter [1 ]
Park, Yeon Hee [2 ]
Munoz-Couselo, Eva [3 ]
Kim, Sung-Bae [4 ]
Sohn, Joohyuk [5 ]
Im, Seock-Ah [6 ]
Holgado, Esther [7 ]
Foukakis, Theodoros [8 ,9 ]
Kuemmel, Sherko [10 ]
Dent, Rebecca [11 ]
Sun, Yuan [12 ]
Huang, Lingkang [12 ]
Yearley, Jennifer [12 ]
Jelinic, Petar [12 ]
Karantza, Vassiliki [12 ]
Cortes, Javier [3 ]
机构：
[1] Ctr Expt Canc Med, London, England
[2] Samsung Med Ctr, Seoul, South Korea
[3] Vall dHebron Inst Oncol VHIO, Barcelona, Spain
[4] Univ Ulsan, Asan Med Ctr, Coll Med, Seoul, South Korea
[5] Yonsei Univ, Yonsei Canc Ctr, Coll Med, Seoul, South Korea
[6] Seoul Natl Univ, Coll Med, Canc Res Inst, Seoul Natl Univ Hosp, Seoul, South Korea
[7] Ramon y Cajal Univ, Madrid, Spain
[8] Karolinska Inst, Solna, Sweden
[9] Karolinska Univ Hosp, Theme Canc, Breast Canc Ctr, Solna, Sweden
[10] Kliniken Essen Mitte, Essen, Germany
[11] Int Breast Canc Ctr Quironsalud Grp, Singapore, Singapore
[12] Merck & Co Inc, Kenilworth, NJ USA
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2021年 / 9卷
关键词：
D O I：
10.1136/jitc-2021-SITC2021.338
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
338
引用
收藏
页码：A364 / A364
页数：1
相关论文
共 50 条
  • [41] Phase II study of pembrolizumab in combination with lenvatinib in patients with triple negative breast cancer (TNBC), non-small cell lung cancer (NSCLC), and other tumor types and brain metastases
    Dumbrava, Ecaterina E.
    Montazari, Emma J.
    Vu, Uyen M.
    Cai, Tiantian
    Altan, Mehmet
    Ibrahim, Nuhad K.
    Yeboa, Debra N.
    Li, Jing
    Lang, Frederick F.
    Sanchez, Gisela
    Glitza, Isabella C.
    O'Brien, Barbara J.
    Murthy, Rashmi K.
    Wang, Jianbo
    Darko, Tanisha T.
    Velazquez, Denisse
    Shah, Komal
    Meric-Bernstam, Funda
    Tawbi, Hussein
    Rodon, Jordi
    CANCER RESEARCH, 2024, 84 (07)
  • [42] KEYNOTE-522: Phase III study of pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo plus chemo as neoadjuvant therapy followed by pembro vs placebo as adjuvant therapy for triple-negative breast cancer (TNBC).
    Schmid, Peter
    Cortes, Javier
    Bergh, Jonas C. S.
    Pusztai, Lajos
    Denkert, Carsten
    Verma, Sunil
    McArthur, Heather L.
    Kummel, Sherko
    Ding, Yu
    Karantza, Vassiliki
    Dang, Thao
    Dent, Rebecca Alexandra
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [43] KEYNOTE-522 Asian subgroup: Phase III study of neoadjuvant pembrolizumab (pembro) vs placebo (pbo) plus chemotherapy (chemo) followed by adjuvant pembro vs pbo for early triple-negative breast cancer (TNBC)
    Dent, R.
    Cortes, J.
    Pusztai, L.
    McArthur, H. L.
    Kuemmel, S.
    Bergh, J.
    Denkert, C.
    Park, Y. H.
    Hui, R.
    Harbeck, N.
    Takahashi, M.
    Foukakis, T.
    Fasching, P. A.
    Cardoso, F.
    Jia, L.
    Jensen, E.
    Karantza, V.
    Aktan, G.
    O'Shaughnessy, J.
    Schmid, P.
    ANNALS OF ONCOLOGY, 2020, 31 : S1241 - S1242
  • [44] Imprime PGG, a soluble yeast beta-glucan PAMP, converts the immunosuppressive myeloid tumor microenvironment into an immunoactive one: translation of preclinical findings to melanoma and triple-negative breast cancer (TNBC) patients
    Uhlik, M.
    Chan, A.
    Harrison, B.
    Jonas, A.
    Gorden, K.
    Qiu, X.
    Ottoson, N.
    Walsh, R.
    Gargano, M.
    Chisamore, M.
    Lowe, J.
    Osterwalder, B.
    Bose, N.
    Graff, J.
    EUROPEAN JOURNAL OF CANCER, 2018, 103 : E82 - E82
  • [45] MAJOR PATHOLOGIC RESPONSE AFTER A SINGLE RADIOTHERAPY FRACTION plus A SINGLE PEMBROLIZUMAB DOSE GIVEN PREOPERATIVELY IN PATIENTS WITH CT1N0 TRIPLE NEGATIVE BREAST CANCER (TNBC) - PRELIMINARY RESULTS OF A PHASE 1B/2 STUDY (NCT04454528)
    Tchou, Julia
    Clark, Amy
    Taunk, Neil
    Freedman, Gary
    Xu, Nucleus
    Minn, Andy
    Bradbury, Angela
    Gross, Angela Demichele
    Domchek, Susan
    Knollman, Hayley
    Jankowitz, Rachel
    Shah, Payal
    Fayanju, Oluwadamilola
    Nayak, Anupma
    Fraietta, Joseph
    Huang, Alexander
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A675 - A675
  • [46] Impact of pembrolizumab versus chemotherapy on health-related quality of life in patients with metastatic triple-negative breast cancer: results from the phase 3 randomised KEYNOTE-119 study
    Schmid, Peter
    Lipatov, Oleg
    Im, Seock-Ah
    Goncalves, Anthony
    Munoz-Couselo, Eva
    Lee, Keun Seok
    Tamura, Kenji
    Testa, Laura
    Witzel, Isabell
    Ohtani, Shoichiro
    Turner, Nicholas
    Zambelli, Stefania
    Harbeck, Nadia
    Andre, Fabrice
    Dent, Rebecca
    Mejia, Jaime A.
    Zhou, Xuan
    Haiderali, Amin
    Nguyen, Allison Martin
    Cortes, Javier
    Winer, Eric P.
    EUROPEAN JOURNAL OF CANCER, 2023, 195
  • [47] First-in-human phase 1/1b expansion of PMD-026, an oral RSK inhibitor, in patients with metastatic triple-negative breast cancer.
    Beeram, Muralidhar
    Chalasani, Pavani
    Wang, Judy S.
    Mina, Lida A.
    Shatsky, Rebecca Arielle
    Trivedi, Meghna S.
    Wesolowski, Robert
    Hurvitz, Sara A.
    Han, Hyo S.
    Patnaik, Amita
    Pambid, Mary Rose
    Jayanthan, Aarthi
    Huynh, My-My
    Los, Gerrit
    Dunn, Sandra Elaine
    Dorr, Andrew
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [48] Phase 2 study of pembrolizumab as first-line therapy for PD-L1-positive metastatic triple-negative breast cancer (mTNBC): Preliminary data from KEYNOTE-086 cohort B.
    Adams, Sylvia
    Loi, Sherene
    Toppmeyer, Deborah
    Cescon, David W.
    De laurentiis, Michele
    Nanda, Rita
    Winer, Eric P.
    Mukai, Hirofumi
    Tamura, Kenji
    Armstrong, Anne
    Liu, Minetta C.
    Iwata, Hiroji
    Ryvo, Larisa
    Wimberger, Pauline
    Card, Deborah
    Ding, Yu
    Karantza, Vassiliki
    Schmid, Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [49] Health-related quality of life (HRQoL) with pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo (pbo) + chemo as 1L treatment for advanced triple-negative breast cancer (TNBC): Results from KEYNOTE-355
    Cescon, D. W.
    Schmid, P.
    Rugo, H. S.
    Im, S-A.
    Yusof, M. Md
    Gallardo, C. E.
    Lipatov, O.
    Barrios, C. H.
    Perez Garcia, J. M.
    Iwata, H.
    Masuda, N.
    Torregroza Otero, M. A.
    Gokmen, E.
    Loi, S.
    Haiderali, A.
    Zhou, X.
    Guo, Z.
    Nguyen, A. Martin
    Cortes, J.
    ANNALS OF ONCOLOGY, 2022, 33 : S197 - S198
  • [50] TOPACIO/Keynote-162 (NCT02657889): A phase 1/2 study of niraparib plus pembrolizumab in patients (pts) with advanced triple-negative breast cancer or recurrent ovarian cancer (ROC)-Results from ROC cohort.
    Konstantinopoulos, Panagiotis A.
    Waggoner, Steven E.
    Vidal, Gregory A.
    Mita, Monica M.
    Fleming, Gini F.
    Holloway, Robert W.
    Van Le, Linda
    Sachdev, Jasgit C.
    Chapman-Davis, Eloise
    Colon-Otero, Gerardo
    Penson, Richard T.
    Matulonis, Ursula A.
    Kim, Young B.
    Moore, Kathleen N.
    Swisher, Elizabeth M.
    Dezube, Bruce Jeffrey
    Wang, Jing Y.
    Buerstatte, Nathan
    Arora, Sujata
    Munster, Pamela N.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345